506 related articles for article (PubMed ID: 17334085)
1. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
[TBL] [Abstract][Full Text] [Related]
2. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
3. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
5. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.
Sumitani S; Harada M; Kubo H; Ohmori T
Psychiatry Res; 2007 Jan; 154(1):85-92. PubMed ID: 17208418
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
[TBL] [Abstract][Full Text] [Related]
7. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Masi G; Pfanner C; Brovedani P
J Psychiatr Res; 2013 Aug; 47(8):1007-12. PubMed ID: 23664673
[TBL] [Abstract][Full Text] [Related]
10. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
Sun TF; Lin PY; Wu CK
Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
12. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.
Van Ameringen M; Simpson W; Patterson B; Dell'Osso B; Fineberg N; Hollander E; Hranov L; Hranov G; Lochner C; Karamustafalioglu O; Marazziti D; Menchon JM; Nicolini H; Pallanti S; Stein DJ; Zohar J
J Psychopharmacol; 2014 Jun; 28(6):596-602. PubMed ID: 24429223
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
17. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Ramasubbu R; Ravindran A; Lapierre Y
Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
[TBL] [Abstract][Full Text] [Related]
18. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
[TBL] [Abstract][Full Text] [Related]
19. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
